|
|
Barr News (NYSE:BRL)
| Latest Barr Pharma News Headlines | | Date | Time | Source | | | 11/21/2008 | 2:00PM | PRNUS | Barr Shareholders Approve Pending Teva Acquisition
MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. (NASDAQ:TEVA).
"Today's vote demonstrated the overwhelming... More...>> |
| 11/19/2008 | 8:00AM | PRNUS | Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
ALLEGAN, Mich., Nov. 19 /PRNewswire-FirstCall/ -- Perrigo Company (NASDAQ:PRGO)(TASE:PRGO) today acknowledges the settlement of patent litigation brought by Sanofi-Aventis (NYSE:SNY) against Barr Laboratories, Inc. a subsidiary of Barr Pharmaceuticals, Inc. (NYSE:BRL). The suit was brought in the U.S. District Court... More...>> |
| 11/19/2008 | 1:30AM | PRNUS | Barr Announces Agreements on Nasacort(R) AQ, Allegra(R) D-12 and Allegra(R) Patent Challenges
- Settlement and License Agreement for Generic Versions of Nasacort(R) AQ
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort(R... More...>> |
| 11/06/2008 | 7:30AM | PRNUS | Barr Reports Third Quarter 2008 GAAP Earnings of $0.28 Per Share; Adjusted Earnings of $0.83 Per Share
- Higher Generic Oral Contraceptive Sales Drive Generic Revenue Growth
MONTVALE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today reported net earnings of $31 million, or $0.28 per share, on revenues of $737 million for the quarter ended September 30, 2008. The current quarter results... More...>> |
| 11/03/2008 | 1:41PM | PRNUS | Barr Announces Approval of Generic Camptosar(R) Injection, 20 mg/mL
MONTVALE, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Camptosar(R) (irinotecan hydrochloride) Injection, 20... More...>> |
| 10/27/2008 | 5:30PM | PRNUS | Teva and Barr Provide Update on Acquisition
- Barr Announces Debt Amendment
JERUSALEM, Israel and MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Barr Pharmaceuticals, Inc. (NYSE:BRL) announced today that Barr and its syndicate of lending banks, arranged by Bank of America, have agreed to amend Barr's unsecured... More...>> |
| 10/27/2008 | 9:12AM | PRNUS | FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Duramed to Launch First Lower-Dose, Extended-Cycle Oral Contraceptive for the Prevention of Pregnancy
MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New... More...>> |
| 10/24/2008 | 12:46PM | PRNUS | Barr Confirms Patent Challenge of Oxytrol(R)
MONTVALE, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Watson Laboratories, Inc. in connection with its Oxytrol(R) (oxybutynin transdermal system). The Company believes it... More...>> |
| 10/21/2008 | 1:23PM | PRNUS | Barr Confirms Patent Challenge of Opana(R) ER Extended-Release Tablets, 5 mg, 10 mg, 20 mg and 40 mg
MONTVALE, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5... More...>> |
| 10/17/2008 | 4:03PM | PRNUS | Barr Revises Timing of Its Earnings Conference Call to Discuss the Results for the Third Quarter of Calendar 2008 to 9:00 AM Eas
MONTVALE, N.J., Oct. 17 Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the Company has revised the time of its conference call to discuss earnings results for the third quarter of calendar 2008, ended September 30, 2008. The Company revised the time of its Conference Call to 9:00 AM Eastern time on Thursday... More...>> |
| 10/16/2008 | 11:28AM | PRNUS | Barr Says Court of Appeals Upholds 2005 District Court Decision on 1997 Cipro(R) Settlement
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the 2005 decision of the U.S. District Court for the Eastern District of New York, which rejected a challenge to the lawfulness of a 1997 patent litigation... More...>> |
| 10/16/2008 | 10:01AM | PRNUS | Barr Announces Date for Special Shareholder Meeting
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) has been set for November 21, 2008. The meeting will be... More...>> |
| 10/07/2008 | 10:06AM | PRNUS | Barr Will Host An Earnings Conference Call on November 6, 2008 to Discuss the Results for the Third Quarter of Calendar 2008
MONTVALE, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the Company will host a Conference Call at 8:30 AM Eastern time on Thursday, November 6 to discuss earnings results for the third quarter of calendar 2008, ended September 30, 2008. The number to call from within... More...>> |
| 09/25/2008 | 8:00AM | PRNUS | Ready and Willing, but Unable? Survey Reveals Boomers Desire Sex, But Face Physical Challenges
MONTVALE, N.J., Sept. 25 /PRNewswire/ -- While the majority of adults aged 50 to 70 agree that decreased frequency, physical ability to have or desire for sex is expected with age, a recent survey indicates that women were less prepared than men for the physical changes that are often associated with menopause that... More...>> |
| 09/16/2008 | 3:58PM | PRNUS | Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
MONTVALE, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) ER (galantamine... More...>> |
| 09/03/2008 | 2:00PM | PRNUS | Teva and Barr Receive FTC Request for Additional Information
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Barr Pharmaceuticals, Inc. (NYSE:BRL) announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal... More...>> |
| 08/28/2008 | 12:18PM | PRNUS | Barr Receives Approval for Generic Version of Razadyne(R) Tablets
MONTVALE, N.J., Aug. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) (galantamine hydrobromide... More...>> |
| 08/28/2008 | 8:48AM | PRNUS | Barr Announces Favorable Ruling in Razadyne(R) Patent Challenge
MONTVALE, NJ, Aug. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the U.S. District Court for the District of Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of U.S. Patent No. 4,663,318 ("the '318 patent") listed by Ortho McNeil Janssen... More...>> |
| 08/25/2008 | 9:33AM | PRNUS | Barr Confirms Patent Challenge of FazaClo(R) Orally Disintegrating Tablets, 25mg and 100mg
MONTVALE, N.J., Aug. 25 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Azur Pharma International in connection with its FazaClo(R) (clozapine) orally disintegrating tablets, 25mg and 100mg... More...>> |
| 08/21/2008 | 12:26PM | PRNUS | /C O R R E C T I O N -- Barr Pharmaceuticals, Inc. (NYSE: BRL)/
In the news release, Barr Pharmaceuticals, Inc. (NYSE: BRL) Announces Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable, issued yesterday, Aug. 20, by Barr Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were the following corrections were made... More...>> |
|
|
|